Following the transaction, the director now directly owns 165,825 shares in the company, valued at approximately $2,316,575.25. The shares were sold at an average price of $13.97, for a total value of $118,745.00. Welgus sold 8,500 shares of the company’s stock in a transaction dated Monday, April 17th. In other Arcutis Biotherapeutics news, Director Howard G. Insider Activity at Arcutis Biotherapeutics will post -4.95 EPS for the current year. As a group, sell-side analysts expect that Arcutis Biotherapeutics, Inc. The business had revenue of $2.78 million during the quarter, compared to analyst estimates of $3.50 million. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.01). Get Arcutis Biotherapeutics alerts:Īrcutis Biotherapeutics ( NASDAQ:ARQT – Free Report) last released its earnings results on Tuesday, May 9th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $45.33. Finally, Needham & Company LLC restated a “buy” rating and set a $24.00 price objective on shares of Arcutis Biotherapeutics in a research report on Wednesday, April 19th. ![]() Truist Financial dropped their price target on Arcutis Biotherapeutics from $45.00 to $40.00 in a research report on Friday, May 26th. ![]() 500.com restated a “reiterates” rating on shares of Arcutis Biotherapeutics in a research report on Monday, June 12th. Mizuho dropped their price objective on shares of Arcutis Biotherapeutics from $61.00 to $57.00 in a research note on Wednesday, May 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, March 1st. Several analysts have recently issued reports on the company. The stock had previously closed at $8.55. 67,135 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 1,128,535 shares. The stock traded as low as $8.11 and last traded at $8.20. ( NASDAQ:ARQT – Free Report) traded down 4.1% during mid-day trading on Tuesday. ![]() We are the antithesis of the big corporate financial companies who put shareholders and corporate profits ahead of the client.Shares of Arcutis Biotherapeutics, Inc. Each of us left large institutions because we wanted to focus on delivering exceptional experiences for our clients unencumbered by corporate conflicts. Together, we develop a plan to help you achieve those outcomes. It’s why we ask a lot of questions – identifying outcomes most meaningful to you. We recognize every client is different and believe investment solutions cannot be determined with a simple questionnaire or algorithm. ![]() We accomplish this through our Team Based Model and comprehensive ARQ planning process. Founded in July of 2008 during the worst financial crisis since the Great Depression, we are advisors for a select few successful entrepreneurs, disciplined savers, and wealth accumulators who strive to live a work optional lifestyle. Answer: ARQ Wealth Advisors is a fully independent, fee-only Registered Investment Advisor firm headquartered in Scottsdale, Arizona and registered with the SEC.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |